BioRestorative Therapies Expands Stem Cell Research with New York State License

Help Spread The Word, Share Post:

In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research.

This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells.

This new license empowers BioRestorative to utilize its cutting-edge cGMP manufacturing facilities for the processing, banking, and distribution of clinical-grade allogeneic (off-the-shelf) biologics.

Such capabilities are crucial for advancing stem cell-based therapies and broadening the scope of regenerative treatments.

The NYSDOH’s licensure process is rigorous, ensuring that all tissue and cell-related activities, including collection, processing, storage, and distribution, meet stringent safety and ethical standards.

Facilities undergo comprehensive on-site evaluations to assess compliance with these regulations.

Lance Alstodt, CEO of BioRestorative Therapies, remarked, “We believe being awarded this expanded provisional license from the NYSDOH serves as a testament to both the ground-breaking nature of our clinical work with stem cell therapies and products, and the outstanding quality of our clinical-grade cell therapy cGMP manufacturing facility.”

This development positions BioRestorative to enhance its clinical pipeline of off-the-shelf cell-based biologic products, potentially accelerating the availability of innovative treatments for patients.

BioRestorative’s core programs include the brtxDISC™ program, focusing on autologous mesenchymal stem cell therapy for lumbar disc disorders, and the ThermoStem® program, targeting obesity and metabolic disorders through brown adipose-derived stem cells.

Additionally, the company offers BioCosmeceutical products, utilizing cell-based secretomes for cosmetic applications.

This expanded license marks a pivotal step in BioRestorative’s mission to advance stem cell research and develop transformative therapies for various medical conditions.

*** All content on NationalStemCellTherapy.com is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

*** Our website contains affiliate advertisements. We may receive a commission for purchases made through these ads at no additional cost to you.

Stay Connected

More Updates